SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Gostner Johanna M.)
 

Search: WFRF:(Gostner Johanna M.) > Serum neopterin lev...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005429naa a2200541 4500
001oai:research.chalmers.se:88be362a-3942-4a7e-a139-f407c3d64f43
003SwePub
008201220s2020 | |||||||||||000 ||eng|
009oai:gup.ub.gu.se/299189
024a https://doi.org/10.1186/s12879-020-05671-72 DOI
024a https://research.chalmers.se/publication/5210812 URI
024a https://gup.ub.gu.se/publication/2991892 URI
040 a (SwePub)cthd (SwePub)gu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
100a Robertson, Josefinau Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine4 aut0 (Swepub:gu)xrobej
2451 0a Serum neopterin levels in relation to mild and severe COVID-19
264 c 2020-12-10
264 1b Springer Science and Business Media LLC,c 2020
338 a electronic2 rdacarrier
520 a Background: The COVID-19 pandemic, caused by the coronavirus SARS-CoV-2, is rapidly spreading worldwide. There is limited information about prognostic markers that could help clinicians to identify COVID-19 patients with a poor prognosis. Serum levels of the immune activation marker neopterin has shown to be of prognostic value in patients with SARS. The aim of this study was to investigate whether serum neopterin is associated with the severity of COVID-19. Methods: We included 34 patients with confirmed COVID-19 between March 3 and March 30, 2020. Fifteen patients had mild disease and did not require hospitalization, whereas 19 patients developed severe COVID-19 requiring intensive care. Concentrations of serum neopterin, tryptophan, and kynurenine were measured at and repeatedly after inclusion. Results: We found a more than two-fold higher mean concentration of neopterin in severely ill patients (mean value 42.0 nmol/L (SD 18.2)) compared to patients with mild symptoms (16.9 nmol/L (SD 11.0)). All of the severe cases had elevated neopterin concentrations (> 9.1 nmol/L) at the initial sampling with values ranging from 17.2 to 86.7 nmol/L. In comparison, 10 of 15 patients with mild disease had neopterin levels above 9.1 nmol/L, with concentrations in the range from 4.9 to 31.6 nmol/L. Neopterin levels gradually decreased during the course of COVID-19, but severe cases maintained elevated levels for a longer period. Moreover, lower levels of tryptophan and higher levels of kynurenine, indicating an increased tryptophan catabolism, were seen in the group with severe cases. Conclusions: In conclusion, we found that serum neopterin levels are associated with the severity of COVID-19. Our findings suggest that neopterin could be used as a prognostic marker, but further studies are needed to elucidate how it can be used in the clinic.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Anestesi och intensivvård0 (SwePub)302012 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Anesthesiology and Intensive Care0 (SwePub)302012 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Klinisk laboratoriemedicin0 (SwePub)302232 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Clinical Laboratory Medicine0 (SwePub)302232 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Gastroenterologi0 (SwePub)302132 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Gastroenterology and Hepatology0 (SwePub)302132 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng
653 a Neopterin
653 a Tryptophan
653 a COVID-19
653 a Kynurenine
653 a Prognostic markers
700a Gostner, Johanna M.u Medizinische Universität Innsbruck,Medical University of Innsbruck4 aut
700a Nilsson, Staffan,d 1956u Gothenburg University,Göteborgs universitet,Institutionen för matematiska vetenskaper,Department of Mathematical Sciences4 aut0 (Swepub:gu)xnista
700a Andersson, Lars-Magnus,d 1968u Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine4 aut0 (Swepub:gu)xalarh
700a Fuchs, D.u Medizinische Universität Innsbruck,Medical University of Innsbruck4 aut
700a Gisslén, Magnus,d 1962u Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine4 aut0 (Swepub:gu)xgissm
710a Göteborgs universitetb Institutionen för biomedicin, avdelningen för infektionssjukdomar4 org
773t BMC Infectious Diseasesd : Springer Science and Business Media LLCg 20:1q 20:1x 1471-2334
856u https://research.chalmers.se/publication/521081/file/521081_Fulltext.pdfx primaryx freey FULLTEXT
856u https://bmcinfectdis.biomedcentral.com/track/pdf/10.1186/s12879-020-05671-7
8564 8u https://doi.org/10.1186/s12879-020-05671-7
8564 8u https://research.chalmers.se/publication/521081
8564 8u https://gup.ub.gu.se/publication/299189

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view